HCW Biologics Inc.
NASDAQHCWB heads into its May 22 earnings report in one of the most extreme short-side configurations of any small-cap biotech currently on the market. The borrow market has essentially seized up. Availability has collapsed to 0% — every share in the lending pool is currently lent out — matching the 52-week low and leaving no room for new shorts to enter without paying up dramatically…
HCWB cost to borrow surges to 771.62%, up 137% in one week, as short interest explodes to 44.4% of float with availability down to zero.
Snapshot as of 23 Jun 2026
HCWB heads into its May 22 earnings report in one of the most extreme short-side configurations of any small-cap biotech currently on the market. The borrow market has essentially seized up. Availability has collapsed…
HCWB (HCW Biologics) has become one of the most aggressively shorted small-cap biotechs in the US market. Short interest has exploded 647% in one week to 44.4% of float. Cost to borrow has hit 772% APR — a record high…
HCW Biologics Inc. reports today with one of the most aggressively shorted lending setups in the small-cap biotech universe — a rare combination of sky-high short interest, near-maximum cost to borrow, and a lending…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for HCWB — free to start on ORTEX.
Sign up for free →Open HCWB on ORTEXPulses are triggered by ORTEX's live data feeds. The full signal history, thresholds, and alerts are on ORTEX.
Live HCWB data →